Skip to contentW
West Pharmaceutical Services Inc
W
WSTWest Pharmaceutical Services Inc Source filing unavailable
Q3 2013 · —
Revenue$341.80M$341.80M+12.5% vs Q3 2012 Net Income$26.80M$26.80M+81.1% vs Q3 2012 EPS Diluted$0.37$0.37+76.2% vs Q3 2012 Gross Profit$105,500,000+16.7% Operating Income$39,700,000+51.0% Operating Cash Flowderived
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
West Pharmaceutical Services Inc · CIK 105770 · Engraved from SEC EDGAR
$53,300,000
+3.3%
Free Cash Flowderived$24,000,000+6.2% Margins · derivedGross margin30.9%+1.1 pt vs Q3 2012
Operating margin11.6%+3.0 pt vs Q3 2012
Net margin7.8%+3.0 pt vs Q3 2012